Gossamer Bio, Inc. (GOSS) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Faheem Hasnain	Co-Founder, Chief Executive Officer, President & Chairman	908,449	1958
Christian Waage	EVP & General Counsel	583,156	1967
Robert Smith	Chief Commercial Officer	663,713	1969
Bryan Giraudo	Chief Operating Officer & Chief Financial Officer	676,743	1975
Richard Aranda	Chief Medical Officer	677,492	1960
Caryn L. Peterson	Executive Vice President of Regulatory Affairs	0	1959
Matt Cravets	Senior Vice President of Biometrics	0	N/A
Kelly Dawson	Senior Vice President of Program Team Lead	0	N/A
Jeanine Anthony	Senior Vice President of Marketing	0	N/A
Deanna Weber	Executive Vice President of Human Resources	0	N/A
Robert F. Roscigno	Senior Vice President of Clinical Development of Pulmonary Vascular Disease	0	1966
Conor O'Donovan	Senior Vice President of Regulatory Affairs	0	N/A
Jeff Boerneke	General Counsel & Secretary	0	N/A
Louis K. Cherico	Senior Vice President of Finance & Treasury	0	N/A

Name

Title

Pay

Year Born

Faheem Hasnain

Co-Founder, Chief Executive Officer, President & Chairman

908,449

1958

Christian Waage

EVP & General Counsel

583,156

1967

Robert Smith

Chief Commercial Officer

663,713

1969

Bryan Giraudo

Chief Operating Officer & Chief Financial Officer

676,743

1975

Richard Aranda

Chief Medical Officer

677,492

1960

Caryn L. Peterson

Executive Vice President of Regulatory Affairs

1959

Matt Cravets

Senior Vice President of Biometrics

N/A

Kelly Dawson

Senior Vice President of Program Team Lead

N/A

Jeanine Anthony

Senior Vice President of Marketing

N/A

Deanna Weber

Executive Vice President of Human Resources

N/A

Robert F. Roscigno

Senior Vice President of Clinical Development of Pulmonary Vascular Disease

1966

Conor O'Donovan

Senior Vice President of Regulatory Affairs

N/A

Jeff Boerneke

General Counsel & Secretary

N/A

Louis K. Cherico

Senior Vice President of Finance & Treasury

N/A

Description

Gossamer Bio, Inc. operates as a U.S.-based, clinical-stage biopharmaceutical company. Its primary objective is to discover, acquire, advance, and market novel therapeutic solutions, specifically addressing conditions within immunology, inflammatory diseases, and oncology. The company's pipeline highlights several key drug candidates: GB002: An inhaled small molecule designed to inhibit platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT, currently being developed for pulmonary arterial hypertension. GB004: An oral, gut-targeted small molecule in development for treating inflammatory bowel disease. GB5121: An oral, irreversible covalent small molecule that targets Bruton's Tyrosine Kinase (BTK), intended for primary central nervous system lymphoma. GB7208: Another oral small molecule BTK inhibitor, under investigation for multiple sclerosis. To support its drug development initiatives, Gossamer Bio has forged strategic licensing partnerships. It holds agreements with Pulmokine, Inc. for the advancement and commercialization of GB002 and its associated backup compounds. Additionally, the company collaborates with Aerpio Pharmaceuticals, Inc. regarding GB004 and related chemical entities. Founded in 2015, the enterprise was initially known as FSG, Bio, Inc. before rebranding as Gossamer Bio, Inc. in 2017. Its corporate headquarters are situated in San Diego, California.